Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04939116
Recruitment Status : Recruiting
First Posted : June 25, 2021
Last Update Posted : March 23, 2022
Sponsor:
Information provided by (Responsible Party):
Angion Biomedica Corp

Brief Summary:
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.

Condition or disease Intervention/treatment Phase
Glomerular Disease Proteinuria Drug: ANG-3070 Drug: Placebo Phase 2

Detailed Description:
To evaluate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria while on the SOC, as measured by a reduction in the 24-hour urinary protein excretion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Safety and Efficacy of ANG-3070 in Patients With Primary Glomerular Disease and Persistent Proteinuria
Actual Study Start Date : December 24, 2021
Estimated Primary Completion Date : July 31, 2023
Estimated Study Completion Date : August 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 200 mg QD
200 mg of ANG-3070 will be taken once daily for 12 weeks.
Drug: ANG-3070
Orally administered tyrosine kinase inhibitor capsule

Experimental: 400 mg QD
400 mg of ANG-3070 will be taken once daily for 12 weeks
Drug: ANG-3070
Orally administered tyrosine kinase inhibitor capsule

Experimental: 300 mg BID
300 mg of ANG-3070 will be taken twice a day for 12 weeks.
Drug: ANG-3070
Orally administered tyrosine kinase inhibitor capsule

Placebo Comparator: Placebo
Placebo capsules will be taken once or twice daily for 12 weeks.
Drug: Placebo
Orally administered placebo capsule




Primary Outcome Measures :
  1. Percentage change in 24-hour urinary protein excretion at Week 12 [ Time Frame: Week 12 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female participants aged 18 and older.
  2. Diagnosis of a primary glomerular disease confirmed from a past renal biopsy. Participants with genetic forms of FSGS may be enrolled without a renal biopsy if the clinical picture is consistent with the genetic testing results.
  3. Estimated glomerular filtration rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) ≥ 40 mL/min/1.73m2.
  4. Urinary protein excretion ≥ 1 g/day on a 24-hour urine collection.
  5. All participants must be on the SOC therapy, including the maximally tolerated/recommended doses of an ACEi or ARB, but not both.

Exclusion Criteria:

  1. Positive Hepatitis B (HBV), Hepatitis C (HCV), or human immunodeficiency virus (HIV) viral screening; historical or during screening.
  2. Aspartate Aminotransferase (AST) or alanine Aminotransferase (ALT) or total bilirubin > 2 x ULN.
  3. Hemoglobin A1C > 8.5%.
  4. Known predisposition to bleeding and/or thrombosis
  5. Type I diabetes mellitus.
  6. Renal disease secondary to systemic disease including but not limited to: systemic lupus erythematosus, anti-neutrophil cytoplasmic antibodies -associated diseases, anti-glomerular basement disease, secondary forms of focal segmental glomerulosclerosis, renal diseases associated with para-proteinemias, C3 glomerulopathy, and diabetic kidney disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04939116


Contacts
Layout table for location contacts
Contact: Brandy Dupee 857-378-4302 bdupee@angion.com

Locations
Show Show 30 study locations
Sponsors and Collaborators
Angion Biomedica Corp
Investigators
Layout table for investigator information
Study Director: John Neylan, MD Angion Biomedica
Layout table for additonal information
Responsible Party: Angion Biomedica Corp
ClinicalTrials.gov Identifier: NCT04939116    
Other Study ID Numbers: ANG3070-CKD-201
First Posted: June 25, 2021    Key Record Dates
Last Update Posted: March 23, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Angion Biomedica Corp:
Glomerular Disease
Chronic Kidney Disease
Proteinuria
Additional relevant MeSH terms:
Layout table for MeSH terms
Proteinuria
Urologic Diseases
Urination Disorders
Urological Manifestations